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Figure 2. Relación entre el uso de antimicrobianos (DDDvet/año) 
y mortalidad (%) en dos empresas de carne de ternera, basado 
en 76 ciclos de producción de carne de ternera blanca (2014-
2016, Bélgica) (Bokma et al., no publicado)
ENGLISH VERSION  
OPPORTUNITIES TO IMPROVE THE WELFARE OF VEAL CALVES 
BY REDUCING ANTIMICROBIAL USE
B. Pardon, DVM, Ph.D, Dip. ECBHM
Worldwide the veal industry is specialized in producing high 
quality meat, by fattening excess male calves from the dairy in-
dustry on a milk replacer diet with variable levels of roughage. 
Today veal production is heavily criticized because of using the 
largest amount of antimicrobials of all documented cattle busi-
nesses (N.B. the feedlot industry has not been documented yet). 
For example, in the Netherlands in the benchmark years 2009-
2010, antimicrobial use was 6 animal daily doses (DDDvet)/year 
in dairy cattle, whereas it was 34 DDDvet/animal year in veal 
calves1. This means that an average veal calf received enough 
antimicrobials to be treated for 34 days on an annual basis, or 
17.9% of their lifetime. In Belgium the situation was even worse 
with 60 DDDvet/animal/year2. This intensive antimicrobial use 
resulted in very high levels of antimicrobial resistance in com-
mensal, pathogenic and zoonotic bacteria (e.g. methicillin resis-
tant Staphylococcus aureus, extended spectrum beta-lactamase 
producing Enterobacteriaceae,…) from veal calves3. Transport-
ing and commingling of very young calves from multiple farms of 
origin (e.g. 1.3 calf pro herd of origin in Belgium4) is inherent to 
the veal industry and results in a large infectious pressure and 
ditto disease burden. To tackle this problem, the veal industry 
relied on (predominantly oral) antimicrobial group treatments, 
which resulted in an acceptably low mortality (4.9% ± 0.8 in 
dairy veal calves)5. Today, such high levels of antimicrobial use 
are no longer tolerated in the European union and reduction is 
urgently needed6. As a counter-argument against a too rapid re-
duction, the industry and veterinarians fear that mortality might 
increase if antimicrobial use decreases too much, too fast. 
Historically the veal industry is very susceptible to criticism 
on animal welfare. To improve the situation, European laws on 
feeding (Fe levels, roughage provision) and housing (surface/ 
animal; group housing at the age of 8 weeks) have been in-
stalled already more than 2 decades ago3. However, public con-
cern, especially on the animals need to express natural behav-
ior, remained and as many other food animal business, the veal 
calf industry timely needs to renew its ‘ license to produce’ from 
the consumer. The incidence of non-nutritive oral behavior re-
mains high in the mainstream veal industry7, and the demand for 
alternative housing (e.g. outdoor pens, straw) and feeding (e.g. 
automatic feeders, more roughage) methods is rapidly grow-
ing in some countries, like Switzerland8. Nowadays, the clas-
sic five freedom approach, which is based on survival-critical 
measurements, is more and more replaced by the objective to 
help animals to have ‘lives worth living’.9 Welfare evaluation is 
very complex and it is important to realize that available evalu-
ation schemes, such as the European Welfare Quality project10 
still need extensive on farm evaluation and further simplification 
where possible. Regardless of the evaluation method selected, 
‘freedom of pain, injury and disease’ will remain a crucial aspect 
of welfare. Antimicrobial use mainly acts on this aspect. It is im-
portant to realize that also other industries (feedlots, dairy beef, 
multisite dairy heifer rearing,…) are working with young calves 
from multiple origins. They face exactly the same disease bur-
den and need to reduce antimicrobial use as the veal industry, 
but at present have the advantage of a better welfare percep-
tion by the general public and scientific community. 
In the Netherlands and Belgium, national (legislative) initiatives 
to reduce antimicrobial use in food animals have been initiated 
in 2009 and 2016, respectively. National targets were reduc-
tions in total antimicrobial use of 70% by 2015 in the Nether-
lands and of 50% by 2020 in Belgium. Both countries prohibited 
preventive antimicrobial use and obliged benchmarking and 
antimicrobial susceptibility testing for critical antimicrobial use. 
Treatment guidelines (formularies) have been made available in 
both countries. In this lecture, an overview is provided on how 
the pressure to reduce antimicrobial use induced changes in the 
Belgian veal industry, which might have potential for improved 
welfare in the future. Methods used in a Flemish sensibilization 
campaign towards the veal industry are presented.   
Rational reduction in antimicrobial use and the ‘three pil-
lar’ approach
In the context of antimicrobial use the term ‘rational use’ signi-
fies only using based on reason and logic and optimal for all 
objectives, namely economics (production), welfare and public/
environmental health. In essence, only animals with an evi-
denced bacterial infection should be treated with antimicrobi-
als. Easily stated, but a very difficult objective to realize in herds 
with average sizes of 500 heads, high levels of viral circulation 
and strict economic limitations on the diagnostic budget avail-
able. To guide the veal industry towards a gradual reduction in 
antimicrobial use, without risking welfare or economic issues, 
a demonstration project commissioned by the Flemish govern-
ment was conducted in 2014 in collaboration with the Flem-
ish Animal Health Service (DGZ Vlaanderen). The knowledge 
base for this project was laid in a series of studies documenting 
morbidity, mortality and antimicrobial use in the Belgian veal 
industry and identifying the main pathogens2,5,11. The selected 
communication strategy towards veal farmers, veterinarians 
and veal company owners consisted of three pillars (Figure 1). 
A first pillar held a series of calf selection parameters to assure 
minimal disease risk, and hence minimal antimicrobial use and 
production losses in the calves purchased. A second was dedi-
cated to adequate housing and nutrition. The third pillar focused 
on antimicrobial therapy (prudent use). 
first pillar: calf selection parameters
The aim is to only purchase animals with minimal disease risk. 
In a Canadian study for example, as much as 50% and 25% of 
calves arrived dehydrated and with an abnormal umbilicus or 
diarrhea12. Healthy animals would be less likely to harbor any 
pathogen upon arrival, or allow massive pathogen replication 
upon infection. It is a well-known secret in the veal industry that 
clusters of mortality can occur within calves originating from the 
same herd13. This fact is already used as economic leverage to 
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eter is a clinical examination upon arrival. A slightly enlarged 
umbilicus and severe dehydration were linked with increased 
mortality risk12. Interestingly, antimicrobial use was lower in 
Swiss veal farms having an arrival examination of all calves done 
by the veterinarian14. To what extend the disease history (pre-
vious treatments) of the calf can be linked with performance 
on the veal farm is currently unknown, but interesting to ex-
plore. Another promising technique is thoracic ultrasonography 
to select calves for purchase and targeted treatment upon ar-
rival. Scanning upon arrival has found access to practice, but 
scientific evidence on its economic benefit is currently lacking. 
Selecting animals based on age remains controversial. Older 
calves have less risk for diarrhea, but conflicting study results 
exist4,15. Thin calves are prone to disease, and calves weighing 
less than 51 kg have 2.7 times higher odds for hampered respi-
ration, worsening with reducing weight16. 
Next to origin, general characteristics and clinical examination 
also additional blood parameters can be determined. Adequate 
colostrum uptake is essential to minimize disease risk and as-
sure growth in the first months of life. There are indications that 
dairy and beef farmers provide less well colostrum to calves 
destined to the veal industry17. In calves younger than one week 
cheap screening tests based on serum total protein (cut off= 
51 g/L) can be used upon arrival, despite a high prevalence of 
dehydration (12%) in these animals18. In Europe, calves need to 
be two weeks old before they can be transported. At that age 
serum total protein can no longer be used, but gamma-globulin 
levels (cut off= 7.5 g/L) as determined by electrophoresis or 
radial immune diffusion still can19. Despite that the knowledge 
and possibilities to practically test the animals are available, 
systematic or targeted testing for failure of passive transfer is 
still not done in any major veal company in Belgium or the Neth-
erlands. Recent studies showed that calves that had antibod-
ies against bovine respiratory syncytial virus, parainfluenzavirus 
type III and bovine coronavirus had reduced odds for respiratory 
disease in the first weeks after arrival19. This observation is a 
plea for vaccination of dams or calves on the herds of origin. An 
additional blood parameter of interest to test in Holstein calves 
upon arrival, might be cholesterol given the increased incidence 
of lethal cholesterol deficiency in this breed12. 
In Belgium, and likely worldwide, the dominant respiratory 
pathogens in veal calf rearing were Mycoplasma bovis (100% 
of the herds) and bovine viral diarrhea virus (BVDv) (93.3%)11,20. 
Animals persistently infected (PI) with BVDv had an increased 
risk of mortality (66.6% vs. 4.1% in non-PIs) and chronic pneu-
monia and pleuritis 5,20. Testing neonatal calves for BVDv sta-
tus (antigen) would likely be beneficial to reduce morbidity and 
mortality. Similarly, calves already having M. bovis antibodies 
upon arrival (subacute infection or uptake of colostrum from a 
recently infected dam) had increased risk for respiratory dis-
ease20. M. bovis is a highly contagious disease, rapidly spread-
ing upon arrival and its peak spread coincides with the peak 
of respiratory disease (2-3 weeks after arrival) in veal farms5. 
Assessing calf quality upon purchase based on scientifically un-
derbuilt parameters rather than gut-feeling enables the possibil-
ity of risk classification and targeted treatment of animals upon 
arrival and provides economic leverage to reduce/increase 
price of a poor/good quality calf. A financial compensation for 
better calves will stimulate the herds of origin to assure a good 
body weight, colostrum uptake and vaccination, improving calf 
welfare. 
Second pillar: nutrition and housing
It is outside the scope of this lecture to go into great details on 
the role of nutrition and housing in immunity and disease. This 
paragraph is limited to informing the reader on what communi-
cations were made towards the veal industry, within the frame-
work of the demonstration project to reduce antimicrobial use. 
Adequate nutrition has major effects on the functioning of the 
immune system and hence the animals ability to cope with the 
high infection pressure in veal facilities. Assuring adequate body 
condition creates better protection against cold stress (insula-
tion) and more reserves to mount a prolonged acute phase re-
sponse. Because of the closed nature of diet composition in the 
veal industry, communication on this topic was limited to assur-
ing protein/caloric needs and sufficient levels of iron. To what 
considers housing, the main point of attention was adequate 
ventilation, protecting calves from cold stress and air pollutants. 
Stable ventilation audits with demonstration of ventilation pat-
terns (smoke) were used to sensibilize the target group. Simi-
larly, protocols for adequate cleaning and disinfection (including 
the milk pipes) were provided to the audience. 
third pillar: prudent and responsible antimicrobial use
It is evident that the most rapid reduction in antimicrobial use 
could be obtained by reflecting on one’s current practices. In 
figure 1 an overview of possible short term measures presented 
to the target group is provided, ranked according to feasibility. 
As in the Belgian veal industry, in the benchmark years 2009-
2010 two antibiotics were used in 33% of the group treatments, 
24% for undocumented indications (dysbiosis and nutritional di-
arrhea) and 13.0% as arrival prophylaxis: a massive opportunity 
to reduce2. 
Compliance and achieved results
Antimicrobial use data (2014-2016) from the largest veal prac-
tice in Belgium (295 production cycles from 78 farms) showed 
a 46% reduction in total antimicrobial use compared to 2010 
(26.4 DDDvet/animal/year), and a 96% reduction in the use of 
critically important fluoroquinolones and 3rd and 4th generation 
cephalosporins21. Use in the dairy veal industry is now almost 
similar in Belgium and the Netherlands. It is important to notice 
that this reduction was achieved before the Belgian law became 
active (voluntary change), in contrast to the Netherlands. De-
spite an overall reduction, major differences in antimicrobial 
use between veal companies still existed in Belgium, pointing 
towards the importance to sensibilize the company owners. 
No associations between a lower antimicrobial use and an in-
creased mortality could be evidenced (Figure 2). In contrast, a 
positive association between antimicrobial use and mortality 
appears to be present in veal companies using less antimicro-
bials, whereas no relationship at all was observed in high use 
companies (Bokma et al., under revision).  Mortality averaged 
2.7% ± 1.3 (range: 0-7.0%) in these farms, the lowest number 
reported for any calf industry21.  
Taking a closer look to what measures were taken (predomi-
nantly by the veal veterinarians) most of them lie within the third 
pillar: antimicrobial use. All suggested parameters in this pillar 
(Figure 1) were systematically included, with exception of total 
withdrawal of arrival prophylaxis in every farm. In the second pil-
lar, the veal companies stimulated disinfection between produc-
tion cycles by offering the products to the farmers. Adaptations 
of stable climate were made in selected stables. In contrast, in 
the first pillar, bargaining over calf prices remained limited to 
herd of origin mortality and presence of clinical signs upon pur-
chase. Before 2015, testing calves for BVDv upon arrival would 
signify the use of PCR which was judged economically impos-
sible by the industry and therefore not conducted. However, 
in January 2015, Belgium started an official BVDv eradication 
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positives could no longer be sold. This might in part explain the 
observed reduction in mortality in the veal industry, as about 
0.6% of admitted calves was PI and these animals had low sur-
vival chances20. Despite not yet being implemented systemati-
cally, interest on screening blood parameters, especially those 
related to colostrum uptake, has massively increased and some 
veal companies/veterinary practices plan to offer the service. 
Notice that vaccination was no part of the selected strategy. 
The reason was that at the time of the project insufficient evi-
dence on the effect of vaccinating young animals after a stress-
or (transport and commingling) and at the time of pathogen ex-
posure was available. However, indirect evidence towards dam 
vaccination or vaccination on farm is currently available19. This 
vaccination strategy and many other calf selection parameters 
can only be achieved if dairy/beef producers and the veal indus-
try connect better in the future. In the authors opinion a sustain-
able solution to truly prevent disease and reduce antimicrobial 
use is creating a mutual benefit situation, with higher prices for 
calves with minimal disease risk (vaccinated, adequate colos-
trum uptake and body weight,…). An important side-effect of 
the pressure to reduce antimicrobial use, was that several vet-
erinary practices invested in software to automatize drug regis-
tration. As a consequence, the digital framework for effective 
disease registration at the individual level is currently available 
and offers the opportunity to monitor welfare as well. 
Conclusions
The pressure to reduce antimicrobial use resulted in a rapid and 
massive decrease in Dutch (legislation) and Belgian (voluntary) 
veal calves, apparently without a worrisome increase in mor-
tality. However, this reduction was mainly achieved by adapt-
ing current antimicrobial use practices, not by better disease 
prevention. It is unlikely that this reduced level of antimicro-
bial use will be accepted as an end-stage by the public opinion. 
Therefore, the real challenge for the industry has only begun, 
with investments in better calf quality at purchase (prevention) 
and individualized antimicrobial therapy as key elements for the 
future. The author recommends to all persons involved to kick-
start the simultaneous benchmarking and evaluation of antimi-
crobial use and mortality as a very rough welfare indicator, to 
minimally assure that no animals are deliberately left untreated. 
The digital advancements made in this industry to automatize 
registration of antimicrobial use can easily be further extend-
ed for health and welfare parameters, preparing the veal and 
any other industry commingling young calves (dairy beef, dairy 
heifer rearing…) to get the new ‘license to produce’ from the 
consumer, in full transparency.  
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